查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087434

龐貝氏症市場：2026-2032年全球市場預測（依產品類型、病患類型、治療方案、給藥途徑、診斷途徑及治療施行地點）

Pompe Disease Market by Product, Patient Type, Treatment Regimen, Route Of Administration, Diagnostic Pathway, Site of Care - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，龐貝氏症市場將成長至 50.9 億美元，複合年成長率為 5.43%。

主要市場統計數據
基準年 2025 35.1億美元
預計年份：2026年 37億美元
預測年份 2032 50.9億美元
複合年成長率 (%) 5.43%

龐貝氏症市場概覽

龐貝氏症是一種罕見的遺傳性溶小體儲積症，由GAA基因的致病突變引起，導致酸性α-Glucosidase酶活性不足，並在骨骼肌、心肌和呼吸肌中肝醣累積。已發表的流行病學數據顯示，其整體盛行率約為四萬分之一，但這一數字會因種族、創始人效應和新生兒篩檢調查方法的不同而有顯著差異。

龐貝氏症現狀的變革性變化

目前，龐貝氏症的診斷正經歷顯著的轉變，從基於症狀的診斷轉向透過新生兒篩檢、酵素檢測、乾血斑檢測和確診性分子診斷進行早期發現。 2015年，龐貝氏症被納入美國統一篩檢項目，加速了各州新生兒篩檢的實施，並加強了早期治療（尤其是嬰兒期發病型龐貝氏症）的證據支持。

人工智慧（AI）的累積影響

人工智慧 (AI) 正開始影響龐貝氏症的診療體系，它能夠改善電子健康記錄、實驗室數據、保險理賠記錄和影像工作流程中罕見疾病徵兆的檢測方式。 AI 驅動的模式識別技術有助於識別不明原因的高肌酸激酶血症、重症肌無力、肥厚型心肌病、呼吸衰竭、睡眠呼吸障礙或反覆就診於專科醫生的患者，從而促進早期轉診，透過 GAA 酶檢測和基因檢測進行確診。

關於龐貝氏症的關鍵區域性見解

北美地區仍然是龐貝氏症診斷和治療領域的領先地區，這得益於其廣泛的專科醫療中心、已通過核准的酶替代療法的醫保覆蓋、完善的患者支持體係以及美國新生兒篩檢的進步。加拿大受益於其全民健保體系、臨床遺傳學體系和罕見疾病框架，但各省的就診途徑和報銷時間可能有所不同。

全球健康聯盟各主要群體的具體見解。

在東協地區，加大對新生兒篩檢、基因組醫學和三級神經肌肉疾病中心的投入，正在改善龐貝氏症的早期檢出率。然而，在大都會圈和農村地區之間以及公立和私立醫療系統之間，醫療服務取得仍然存在差距。海灣合作理事會（GCC）國家正透過國家基因組舉措、專科醫院和公共報銷模式，優先發展罕見疾病計畫。這一點至關重要，因為近親結婚可能會增加患有體染色體隱性遺傳疾病（包括溶小體儲積症）的風險。

關於龐貝氏症的關鍵國家見解

美國在新生兒篩檢規模、獲得FDA批准的治療方案、患者權益倡導、參與臨床試驗以及真實世界證據的生成方面主導。加拿大擁有高度專業化的醫療保健體系、公共醫療系統和臨床遺傳學網路，但各省報銷制度的差異可能會影響治療時機。墨西哥和巴西是拉丁美洲的典型案例，在這兩個國家，公共醫療服務的可近性、轉診中心的容量、診斷延誤以及巴西較高的訴訟率都會影響治療路徑和醫療服務的連續性。

為行業領導者提供的實用建議

產業領導者應優先考慮早期診斷，與新生兒篩檢計畫、神經肌肉診所、肺科醫生、心臟科醫生、循環系統專家和基因檢測機構合作。商業性和醫療策略應支持清晰的診斷流程、幹血斑檢測、反射性基因確診檢測、家族級聯檢測以及針對晚髮型龐貝氏症的宣傳活動，以減少數年的診斷延誤。

調查方法

本執行摘要基於二手資料和檢驗，參考了經核實的公開資訊來源，包括美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 的監管文件、新生兒篩檢指南、經同行評審的龐貝氏症文獻、罕見疾病出版刊物、臨床指南出版物以及衛生技術評估 (HTA)資訊來源。研究結果從多個角度進行檢驗，包括流行病學、已通過核准的治療方法、診斷標準、保險報銷趨勢、新生兒篩檢實施情況以及當地醫療保健基礎設施。

結論

目前，龐貝氏症的治療正朝著早期發現、個人化治療和實證療法普及的方向發展。新生兒篩檢、分子診斷、酵素替代療法的創新、呼吸監測和多學科診療正在重新定義嬰兒期發病和晚髮型龐貝氏症的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 龐貝氏症市場：依產品分類

  • 酵素替代療法
    • Glucosidase酶α
    • Glucosidase酶α
    • Glucosidase酶α
  • 基因治療
    • 體內基因轉移
    • 體外基因修飾細胞療法
  • 下一代酵素療法
  • 藥理學Chaperone
  • 基材減少療法
  • mRNA/蛋白質表現療法
  • 支持和輔助性治療

第8章：龐貝氏症市場：依患者類型分類

  • 嬰兒發病型
  • 遲髮型

第9章：龐貝氏症市場：依治療方案分類

  • 每隔一週進行一次靜脈注射
  • 每月一次靜脈注射

第10章：龐貝氏症市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 肌肉內部
  • 皮下
  • 吸入

第11章：龐貝氏症市場：依診斷途徑分類

  • 新生兒篩檢
    • 乾血斑酶檢測法
    • 反射療法基因檢測
  • 診斷檢查和症狀出現
    • 酵素活性測定
    • 基因檢測
    • 生物標記檢測
    • 影像檢查和功能檢查
    • 組織切片檢查
  • 治療監測

第12章：龐貝氏症市場：依治療施行地點

  • 住院病人
  • 獨立靜脈輸液治療中心
  • 家庭靜脈輸液治療
  • 專科診所（代謝和神經肌肉）

第13章：龐貝氏症市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 龐貝氏症市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：龐貝氏症市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Sanofi SA
  • BioMarin Pharmaceutical Inc.
  • Revvity, Inc.
  • Maze Therapeutics, Inc.
  • Laboratory Corporation of America Holdings
  • Baebies, Inc.
  • GENETHON
  • Aro Biotherapeutics
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Denali Therapeutics Inc.
  • Eurofins Scientific SE
  • Illumina, Inc.
  • LaCAR MDx Technologies SA
  • Novartis AG
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Shionogi & Co., Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Valerion Therapeutics, LLC
  • WuXi AppTec
Product Code: MRR-035AB9C0DAD1

The Pompe Disease Market is projected to grow by USD 5.09 billion at a CAGR of 5.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.51 billion
Estimated Year [2026] USD 3.70 billion
Forecast Year [2032] USD 5.09 billion
CAGR (%) 5.43%

Pompe Disease Market Introduction

Pompe disease is a rare, inherited lysosomal storage disorder caused by pathogenic variants in the GAA gene, leading to deficient acid alpha-glucosidase activity and glycogen accumulation in skeletal, cardiac, and respiratory muscle. Published epidemiology commonly cites an overall frequency near 1 in 40,000 births, with meaningful variation by ethnicity, founder effects, and newborn screening methodology.

The Pompe disease landscape is shaped by three clinical realities: infantile-onset Pompe disease can progress rapidly and is often fatal without timely therapy, late-onset Pompe disease is frequently underdiagnosed because symptoms overlap with neuromuscular and respiratory disorders, and lifelong treatment requires coordinated specialty care. Enzyme replacement therapy, newborn screening, genetic testing, respiratory monitoring, immunogenicity management, and multidisciplinary disease care remain central to patient outcomes and strategic planning.

Transformative Shifts in the Pompe Disease Landscape

The Pompe disease landscape is undergoing a measurable transition from symptom-led diagnosis to earlier identification through newborn screening, enzymatic testing, dried blood spot assays, and confirmatory molecular diagnostics. The addition of Pompe disease to the U.S. Recommended Uniform Screening Panel in 2015 accelerated state-level newborn screening adoption and strengthened the evidence base for early treatment, especially in infantile-onset disease.

Treatment competition is also evolving. Long-established alglucosidase alfa therapy created the foundation for disease-modifying care, while newer options such as avalglucosidase alfa and cipaglucosidase alfa plus miglustat have increased attention on improved glycogen clearance, durability, infusion burden, immunogenicity management, and patient-centered outcomes. These shifts are moving stakeholders toward value-based differentiation rather than simple treatment availability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the Pompe disease ecosystem by improving how rare disease signals are detected across electronic health records, laboratory data, claims histories, and imaging workflows. AI-enabled pattern recognition can help flag patients with unexplained hyperCKemia, limb-girdle weakness, hypertrophic cardiomyopathy, respiratory insufficiency, sleep-disordered breathing, or repeated specialist visits, supporting earlier referral for GAA enzyme testing and genetic confirmation.

In drug development and real-world evidence, AI can accelerate patient stratification, natural history modeling, biomarker discovery, and trial feasibility assessment. Its impact remains cumulative rather than instantaneous because Pompe disease datasets are small, privacy-sensitive, and heterogeneous; therefore, the greatest near-term value will come from validated clinical decision support, federated data models, and transparent algorithms aligned with regulatory and ethical expectations.

Key Regional Insights for Pompe Disease

North America remains a leading region for Pompe disease diagnosis and treatment adoption due to broad specialty-center access, payer coverage for approved enzyme replacement therapies, patient advocacy infrastructure, and newborn screening momentum across the United States. Canada benefits from universal health systems, clinical genetics capacity, and rare disease frameworks, although access and reimbursement timing can differ by province.

Europe demonstrates strong clinical infrastructure through neuromuscular centers, cross-border research networks, national rare disease plans, and European Medicines Agency oversight. The European Union supports coordinated rare disease policy and European Reference Networks, while the United Kingdom, Germany, France, Italy, and Spain contribute significant clinical expertise in diagnosis, respiratory care, and long-term follow-up. Asia-Pacific is expanding as Japan, South Korea, Australia, China, and India improve genetic testing capacity, reimbursement pathways, newborn screening pilots, and rare disease policy recognition. Latin America shows growing demand led by Brazil and Mexico, but uneven specialist access, fragmented reimbursement, and delayed diagnosis remain barriers. The Middle East, particularly Gulf countries, is increasing rare disease investment through genomics programs and tertiary hospitals, while Africa continues to face diagnostic capacity constraints, limited therapy access, lower awareness of late-onset Pompe disease, and underdeveloped referral networks.

Key Group Insights Across Global Health Alliances

Within ASEAN, rising investment in newborn screening, genomic medicine, and tertiary neuromuscular centers is improving Pompe disease identification, although access remains uneven between metropolitan and rural populations and across public and private health systems. GCC countries are prioritizing rare disease programs through national genomics initiatives, specialized hospitals, and public reimbursement models, which is relevant because consanguinity can increase the visibility of autosomal recessive disorders, including lysosomal storage diseases.

The European Union provides one of the most coordinated policy environments for Pompe disease through orphan drug regulation, health technology assessment, cross-border care mechanisms, and European Reference Networks. BRICS markets represent both opportunity and complexity: China, India, and Brazil offer large undiagnosed patient populations and expanding diagnostics, while reimbursement, clinical referral pathways, and regional access vary widely; Russia and South Africa add further diversity in public-sector capacity and rare disease prioritization. G7 countries generally lead in approved therapy availability, evidence generation, newborn screening infrastructure, and specialist multidisciplinary care. NATO membership does not directly define healthcare access, but many NATO countries overlap with advanced European and North American rare disease systems, supporting stronger clinical research collaboration, emergency preparedness, and biologics supply-chain resilience.

Key Country Insights in Pompe Disease

The United States leads in newborn screening scale, FDA-approved therapy access, patient advocacy, clinical trial participation, and real-world evidence generation. Canada has strong specialty care, public health systems, and clinical genetics networks, but province-specific reimbursement dynamics can influence treatment timing. Mexico and Brazil are important Latin American settings where public-sector access, reference-center capacity, diagnostic delays, and judicialization in Brazil influence treatment pathways and continuity of care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established neuromuscular expertise, reimbursement systems, respiratory care pathways, and rare disease networks, while Russia's access environment is more variable across regions. China is expanding rare disease policy, genetic testing, newborn screening research, and domestic clinical studies; India has a large potential undiagnosed population but faces affordability, awareness, and access challenges. Japan and South Korea are advanced Asia-Pacific settings with strong regulatory systems, specialist centers, and newborn screening experience, and Australia benefits from organized rare disease care, public reimbursement mechanisms, clinical genetics infrastructure, and national attention to genomic medicine.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize earlier diagnosis by partnering with newborn screening programs, neuromuscular clinics, pulmonologists, cardiologists, metabolic specialists, and genetic testing providers. Commercial and medical strategies should support clear diagnostic algorithms, dried blood spot testing, reflex genetic confirmation, family cascade testing, and education on late-onset Pompe disease to reduce multi-year diagnostic delays.

Therapy differentiation should be anchored in outcomes that matter to patients, clinicians, and payers, including ventilator-free survival in infantile-onset disease, motor function, respiratory function, fatigue, mobility, infusion burden, safety, immunogenicity, and quality of life. Organizations should invest in real-world evidence registries, equitable access programs, decentralized monitoring, home-infusion readiness where clinically appropriate, and compliant AI tools that improve case finding without compromising privacy or clinical accountability.

Research Methodology

This executive summary is developed through secondary research and expert synthesis of verified public sources, including regulatory agency materials from the FDA and EMA, newborn screening guidance, peer-reviewed Pompe disease literature, orphan disease registries, clinical guideline publications, and health technology assessment references. Insights are triangulated across epidemiology, approved therapies, diagnostic standards, reimbursement dynamics, newborn screening implementation, and regional healthcare infrastructure.

The methodology emphasizes data integrity over speculative claims. Findings are interpreted using rare disease analysis, clinical pathway mapping, policy review, and comparative regional assessment. Where quantitative estimates vary, the summary uses conservative, widely cited ranges and highlights geographic variability rather than presenting unsupported projections.

Conclusion

The Pompe disease landscape is moving toward earlier detection, more differentiated treatment, and evidence-driven access. Newborn screening, molecular diagnostics, enzyme replacement innovation, respiratory monitoring, and multidisciplinary care are redefining outcomes for both infantile-onset and late-onset Pompe disease.

For stakeholders, the strongest opportunities lie in reducing diagnostic delay, proving real-world value, expanding equitable access, and integrating responsible AI into rare disease workflows. Organizations that align clinical evidence, patient experience, and payer expectations will be best positioned in the evolving Pompe disease landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pompe Disease Market, by Product

  • 7.1. Enzyme Replacement Therapy
    • 7.1.1. Alglucosidase Alfa
    • 7.1.2. Avalglucosidase Alfa
    • 7.1.3. Cipaglucosidase Alfa
  • 7.2. Gene Therapy
    • 7.2.1. In Vivo Gene Transfer
    • 7.2.2. Ex Vivo Gene-Modified Cell Therapy
  • 7.3. Next-Generation Enzyme Therapies
  • 7.4. Pharmacological Chaperones
  • 7.5. Substrate Reduction Therapy
  • 7.6. mRNA/Protein Expression Therapies
  • 7.7. Supportive/Adjunctive Care

8. Pompe Disease Market, by Patient Type

  • 8.1. Infantile Onset
  • 8.2. Late Onset

9. Pompe Disease Market, by Treatment Regimen

  • 9.1. Biweekly Infusion
  • 9.2. Monthly Infusion

10. Pompe Disease Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Intramuscular
  • 10.4. Subcutaneous
  • 10.5. Inhaled

11. Pompe Disease Market, by Diagnostic Pathway

  • 11.1. Newborn Screening
    • 11.1.1. Dried Blood Spot Enzyme Assay
    • 11.1.2. Reflex Genetic Testing
  • 11.2. Diagnostic Testing & Symptom Onset
    • 11.2.1. Enzyme Activity Assay
    • 11.2.2. Genetic Testing
    • 11.2.3. Biomarker Testing
    • 11.2.4. Imaging & Functional Testing
    • 11.2.5. Tissue Biopsy
  • 11.3. Treatment Monitoring

12. Pompe Disease Market, by Site of Care

  • 12.1. Hospital Inpatient
  • 12.2. Standalone Infusion Center
  • 12.3. Home Infusion
  • 12.4. Specialty Clinic (Metabolic/Neuromuscular)

13. Pompe Disease Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Pompe Disease Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pompe Disease Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Sanofi SA
  • 17.2. BioMarin Pharmaceutical Inc.
  • 17.3. Revvity, Inc.
  • 17.4. Maze Therapeutics, Inc.
  • 17.5. Laboratory Corporation of America Holdings
  • 17.6. Baebies, Inc.
  • 17.7. GENETHON
  • 17.8. Aro Biotherapeutics
  • 17.9. Astellas Pharma Inc.
  • 17.10. Bayer AG
  • 17.11. Bio-Rad Laboratories, Inc.
  • 17.12. Bio-Techne Corporation
  • 17.13. Catalent, Inc.
  • 17.14. Charles River Laboratories International, Inc.
  • 17.15. Denali Therapeutics Inc.
  • 17.16. Eurofins Scientific SE
  • 17.17. Illumina, Inc.
  • 17.18. LaCAR MDx Technologies S.A.
  • 17.19. Novartis AG
  • 17.20. QIAGEN N.V.
  • 17.21. Quest Diagnostics Incorporated
  • 17.22. Shionogi & Co., Ltd.
  • 17.23. Siemens Healthineers AG
  • 17.24. Thermo Fisher Scientific Inc.
  • 17.25. Valerion Therapeutics, LLC
  • 17.26. WuXi AppTec

LIST OF FIGURES

  • FIGURE 1. GLOBAL POMPE DISEASE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL POMPE DISEASE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL POMPE DISEASE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL POMPE DISEASE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ALGLUCOSIDASE ALFA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ALGLUCOSIDASE ALFA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ALGLUCOSIDASE ALFA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AVALGLUCOSIDASE ALFA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AVALGLUCOSIDASE ALFA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AVALGLUCOSIDASE ALFA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CIPAGLUCOSIDASE ALFA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CIPAGLUCOSIDASE ALFA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CIPAGLUCOSIDASE ALFA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IN VIVO GENE TRANSFER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IN VIVO GENE TRANSFER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IN VIVO GENE TRANSFER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EX VIVO GENE-MODIFIED CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EX VIVO GENE-MODIFIED CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EX VIVO GENE-MODIFIED CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION ENZYME THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION ENZYME THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION ENZYME THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOLOGICAL CHAPERONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOLOGICAL CHAPERONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOLOGICAL CHAPERONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRNA/PROTEIN EXPRESSION THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRNA/PROTEIN EXPRESSION THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRNA/PROTEIN EXPRESSION THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SUPPORTIVE/ADJUNCTIVE CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SUPPORTIVE/ADJUNCTIVE CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SUPPORTIVE/ADJUNCTIVE CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFANTILE ONSET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFANTILE ONSET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFANTILE ONSET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LATE ONSET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LATE ONSET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LATE ONSET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIWEEKLY INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIWEEKLY INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIWEEKLY INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MONTHLY INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONTHLY INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONTHLY INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INHALED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INHALED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INHALED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRIED BLOOD SPOT ENZYME ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRIED BLOOD SPOT ENZYME ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRIED BLOOD SPOT ENZYME ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL REFLEX GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL REFLEX GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL REFLEX GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC TESTING & SYMPTOM ONSET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC TESTING & SYMPTOM ONSET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTIC TESTING & SYMPTOM ONSET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENZYME ACTIVITY ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENZYME ACTIVITY ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENZYME ACTIVITY ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOMARKER TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOMARKER TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOMARKER TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMAGING & FUNCTIONAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMAGING & FUNCTIONAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMAGING & FUNCTIONAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL STANDALONE INFUSION CENTER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL STANDALONE INFUSION CENTER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL STANDALONE INFUSION CENTER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOME INFUSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOME INFUSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOME INFUSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SPECIALTY CLINIC (METABOLIC/NEUROMUSCULAR) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SPECIALTY CLINIC (METABOLIC/NEUROMUSCULAR) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SPECIALTY CLINIC (METABOLIC/NEUROMUSCULAR) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. GCC POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 198. GCC POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. GCC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 201. GCC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 202. GCC POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 227. G7 POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 231. G7 POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 234. G7 POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 235. G7 POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 238. NATO POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 242. NATO POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. NATO POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 244. NATO POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 245. NATO POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 246. NATO POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 259. CANADA POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. CANADA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 261. CANADA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. CANADA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. CANADA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. CANADA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 270. MEXICO POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. MEXICO POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 272. MEXICO POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. MEXICO POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. MEXICO POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. MEXICO POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 276. MEXICO POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 281. BRAZIL POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. BRAZIL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 283. BRAZIL POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. BRAZIL POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. BRAZIL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. BRAZIL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 287. BRAZIL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. BRAZIL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 303. GERMANY POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. GERMANY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 305. GERMANY POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. GERMANY POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. GERMANY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. GERMANY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 309. GERMANY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. GERMANY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 311. GERMANY POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 312. GERMANY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 314. FRANCE POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. FRANCE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 316. FRANCE POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. FRANCE POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. FRANCE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. FRANCE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 320. FRANCE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 321. FRANCE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 322. FRANCE POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 323. FRANCE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 324. FRANCE POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 325. RUSSIA POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. RUSSIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 327. RUSSIA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. RUSSIA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 329. RUSSIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. RUSSIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 331. RUSSIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 332. RUSSIA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 333. RUSSIA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 334. RUSSIA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 335. RUSSIA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 336. ITALY POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 337. ITALY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 338. ITALY POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 339. ITALY POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 340. ITALY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. ITALY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 342. ITALY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 343. ITALY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 344. ITALY POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 345. ITALY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 346. ITALY POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 347. SPAIN POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 348. SPAIN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 349. SPAIN POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 350. SPAIN POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 351. SPAIN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. SPAIN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 353. SPAIN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 354. SPAIN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 355. SPAIN POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2018-2032 (USD MILLION)
  • TABLE 356. SPAIN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2018-2032 (USD MILLION)
  • TABLE 357. SPAIN POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2018-2032 (USD MILLION)
  • TABLE 358. CHINA POMPE DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 359. CHINA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 360. CHINA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 361. CHINA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 362. CHINA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 363. CHINA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 364. CHINA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 365. CHINA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 366. CHINA POMPE DISEASE MARKET SIZE, BY